Cros

RealTime Software Solutions Acquires Complion

Retrieved on: 
Wednesday, December 7, 2022

SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).

Key Points: 
  • SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).
  • The partnership of RealTime and Complion bolsters the combined organization's position as a leading provider of eClinical solutions to make clinical research processes more efficient and compliant.
  • "This combination accelerates our mission to deliver leading eRegulatory and additional innovative solutions from RealTime to our customers."
  • About RealTime: RealTime Software Solutions, LLC provides innovative software solutions for clinical research sites, site networks, sponsors and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done.

Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program

Retrieved on: 
Wednesday, December 7, 2022

PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that as part of its single platform rollout, its electronic clinical outcome assessments (eCOA) solution is moving to the second phase of the Early Adopter program. This solution, designed to work seamlessly with Suvoda IRT and eConsent, focuses on tackling the historical inefficiencies that continue to plague eCOA, such as gaps in overall delivery and execution quality, time consuming translations and localization processes, and logistics related to device management.

Key Points: 
  • "In support of Suvoda's mission to enhance the clinical trial process, Suvoda did not want to simply offer another eCOA solution.
  • Within it, Suvoda offers a proprietary domain-specific language and creation tool that is tailor-made for eCOA questionnaires.
  • Questionnaires also can be defined, adjusted, translated, validated, and reused across modalities and devices, all in a regulatory-compliant environment.
  • Suvoda is still accepting participants in the Early Adopter program as eCOA moves into the next phase.

Suvoda Launches eCOA-Specific Language and Design Toolkit as Solution Moves to Second Phase of Early Adopter Program

Retrieved on: 
Wednesday, December 7, 2022

PHILADELPHIA, Dec. 7, 2022 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare disease, today announced that as part of its single platform rollout, its electronic clinical outcome assessments (eCOA) solution is moving to the second phase of the Early Adopter program. This solution, designed to work seamlessly with Suvoda IRT and eConsent, focuses on tackling the historical inefficiencies that continue to plague eCOA, such as gaps in overall delivery and execution quality, time consuming translations and localization processes, and logistics related to device management.

Key Points: 
  • "In support of Suvoda's mission to enhance the clinical trial process, Suvoda did not want to simply offer another eCOA solution.
  • Within it, Suvoda offers a proprietary domain-specific language and creation tool that is tailor-made for eCOA questionnaires.
  • Questionnaires also can be defined, adjusted, translated, validated, and reused across modalities and devices, all in a regulatory-compliant environment.
  • Suvoda is still accepting participants in the Early Adopter program as eCOA moves into the next phase.

Global 3D Protein Structure Analysis Market Report 2022-2032: Increase in R&D Expenditure in Drug Discovery and Development & Focus on Automation and Miniaturization in X-Ray Crystallography Workflow

Retrieved on: 
Tuesday, December 6, 2022

In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032

Key Points: 
  • In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032
    The growth in the global 3D protein structure analysis market is expected to be driven by technological advancements in equipment for protein structure analysis and by an increase in R&D expenditure to accelerate protein structure analysis.
  • Leading manufacturers like Bruker Corporation, JEOL Ltd., and Spectris plc provide equipment for 3D protein structure analysis according to one's needs.
  • Based on product, the global 3D protein structure analysis market is expected to be dominated by the consumable segment.
  • The presence of major equipment providers of 3D protein structure analysis has a major impact on the market.

Trialjectory Grows Pharmaceutical and Biotech Clinical Trial Partnerships by 800 Percent

Retrieved on: 
Monday, December 5, 2022

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Trialjectory ("the Company"), an AI-powered decision support platform that democratizes patient access to advanced cancer treatments and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials, announced today it is currently working with more than 50 pharmaceutical companies, emerging biotechs and Contract Research Organizations to develop and execute clinical trials that focus more on patients' unique medical and personal needs – an increase of 800 percent since the beginning of 2020.

Key Points: 
  • With more than 3 million treatment matches to date, Trialjectory has grown its database from 2,000 clinical trials in 2019 to over 20,000 trials in 2022.
  • "The first step toward increasing all enrollment in clinical studies is to address the fears and myths about what it means to participate in a clinical trial.
  • "Since partnering with Trialjectory, MPNRF has accelerated clinical trial access for patients living with myeloproliferative neoplasms (MPN).
  • Working directly with patients, healthcare providers and pharmaceutical companies, Trialjectory democratizes access to advanced cancer treatment and empowers the pharmaceutical and biotech industry to execute more patient-centric clinical trials.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

Bank Chief Risk Officers Under Increasing Pressure as Recession Looms

Retrieved on: 
Thursday, December 1, 2022

PHILADELPHIA and NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Chief Risk Officers are balancing a wide range of demands heading into 2023 – a year in which many emerging risks may be realized, the CRO Outlook 2023 study by the Risk Management Association and global management consultancy Oliver Wyman has found. In addition, North American bank CROs representing institutions with assets ranging from $25 billion to over $1 trillion say economic worries and the need to prepare for potential recession are piling on top of non-financial risks like consumer compliance, cyber threats, and climate risk.

Key Points: 
  • Climate and ESG risk also remain high on the CRO risk agenda.
  • "At RMA, we are focused on supporting Bank CROs and all financial risk professionals as macroeconomic headwinds create further challenges," RMA President and CEO Nancy Foster said.
  • "Risk officers have their fingers on the pulse of threats to their companies' success and on opportunities that lie in change.
  • RMA promotes an enterprise approach to risk management that focuses on credit risk, market risk, and operational risk.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

Global 3D Protein Structure Analysis Markets Report 2022-2032: Advancements in Equipment for Protein Structure Analysis and An Increase in R&D Expenditure to Accelerate Protein Structure Analysis - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032

Key Points: 
  • In 2021, the global 3D protein structure analysis market was valued at $1,017.2 million, and it is expected to reach $2,676.6 million by 2032, growing at a CAGR of 9.32% during the forecast period 2022-2032
    The growth in the global 3D protein structure analysis market is expected to be driven by technological advancements in equipment for protein structure analysis and by an increase in R&D expenditure to accelerate protein structure analysis.
  • Leading manufacturers like Bruker Corporation, JEOL Ltd., and Spectris plc provide equipment for 3D protein structure analysis according to one's needs.
  • Based on product, the global 3D protein structure analysis market is expected to be dominated by the consumable segment.
  • The presence of major equipment providers of 3D protein structure analysis has a major impact on the market.

GHO Capital invests in Sapio Sciences, a leading, high growth lab informatics platform company

Retrieved on: 
Thursday, December 1, 2022

The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.

Key Points: 
  • The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose.
  • GHOs support and investment will allow Sapio to explore multiple avenues for growth and expansion for the company, product offering and global footprint.
  • The Partners at GHO Capital, said, The trend towards adopting lab informatics solutions is accelerating.
  • Sapio provides LIMS, ELN, and Scientific Data Management Solutions through its flexible, scalable, and easy-to-use Seamless Informatics Platform.